0001387131-20-006276.txt : 20200709
0001387131-20-006276.hdr.sgml : 20200709
20200709205853
ACCESSION NUMBER: 0001387131-20-006276
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200709
FILED AS OF DATE: 20200709
DATE AS OF CHANGE: 20200709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39370
FILM NUMBER: 201021585
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nkarta, Inc.
CENTRAL INDEX KEY: 0001787400
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474515206
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-215-0385
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
3
1
gsk-form3_070920.xml
OWNERSHIP DOCUMENT
X0206
3
2020-07-09
0
0001787400
Nkarta, Inc.
NKTX
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
1
0
1
0
Series A Preferred Stock
Common Stock
525499
I
See footnote
Series B Preferred Stock
Common Stock
1712810
I
See footnote
The Series A Preferred Stock is convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The Series B Preferred Stock is convertible at a conversion rate of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Gives effect to the one-for-3.7 reverse stock split of the Issuer's common stock and a proportional adjustment to the conversion ratio of the Series A Preferred Stock and Series B Preferred Stock, effective on July 1, 2020.
The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.
/s/ Victoria Whyte
2020-07-09